Literature DB >> 11005227

Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa.

G Tuccari1, G Giuffrè, F Arena, G Barresi.   

Abstract

Utilising a specific monoclonal mouse antibody (E9), metallothionein (MT) expression has been immunohistochemically investigated in 112 formalin-fixed paraffin-embedded surgical gastric samples, 38 of which were early carcinomas (EGC) and 74 advanced ones (AGC); clinico-pathological details and follow-up data (ranging from 3 to 197 months, mean 60.5 months) were available. Eighty-nine portions of gastric mucosa adjacent to examined carcinomas (transitional mucosa) were also analysed; in addition, 22 biopsies of normal gastric mucosa were studied as tissue control. The MT immunoreactivity was evaluated by staining and intensity-distribution scores. A various MT positivity was appreciable in the cytoplasm and nucleus of antrum or body gastric epithelial cells in 100% of normal control biopsies. 75/112 (67%) gastric carcinomas showed MT immunoreactivity with a significant lower expression in AGC. No relationships were encountered between MT immunostaining and clinico-pathological data; in addition, no difference in the Kaplan-Meier survival curves of patients with various MT expression was achieved. When the transitional mucosa was examined, 84/89 (94%) samples were stained although the immunoreaction was not always concordant with that encountered in adjacent carcinomatous elements. The significant statistical decrease of MT scores observed by us moving from normal to neoplastic gastric mucosa allows us to exclude the hypothesis of an overexpression of MT in gastric carcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005227     DOI: 10.14670/HH-15.1035

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  6 in total

Review 1.  Metallothionein Lower Under-Expression in Benign Tumors than That in Malignant Tumors: Systematic Review Article and Meta-Analysis.

Authors:  Jie Zhang; Ruijie Sun; Yue Liu; Guinian Wang; Qinglu Wang
Journal:  Iran J Public Health       Date:  2014-06       Impact factor: 1.429

2.  Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.

Authors:  Jaromir Gumulec; Martina Raudenska; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

3.  Trace metals and over-expression of metallothioneins in bladder tumoral lesions: a case-control study.

Authors:  André F S Amaral; Teresa Cymbron; Fátima Gärtner; Manuela Lima; Armindo S Rodrigues
Journal:  BMC Vet Res       Date:  2009-07-18       Impact factor: 2.741

4.  Apoptosis, metallothionein, and bioavailable metals in domestic mice (Mus musculus L.) from a human-inhabited volcanic area.

Authors:  André Amaral; Carolina Cabral; Cláudia Guedes; Armindo Rodrigues
Journal:  Ecotoxicology       Date:  2007-06-23       Impact factor: 2.935

5.  Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection.

Authors:  Yuanming Pan; Jiaqiang Huang; Rui Xing; Xin Yin; Jiantao Cui; Wenmei Li; Jun Yu; Youyong Lu
Journal:  J Transl Med       Date:  2013-07-19       Impact factor: 5.531

6.  Evaluation of MT Family Isoforms as Potential Biomarker for Predicting Progression and Prognosis in Gastric Cancer.

Authors:  Mingfu Tong; Wenquan Lu; Hao Liu; Jian Wu; Mingzuo Jiang; Xin Wang; Jianyu Hao; Daiming Fan
Journal:  Biomed Res Int       Date:  2019-07-17       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.